Basilea Pharmaceutica (Switzerland) Today
| BSLN Stock | CHF 41.95 0.25 0.60% |
Performance11 of 100
| Odds Of DistressLess than 28
|
Basilea Pharmaceutica is selling for under 41.95 as of the 19th of April 2024; that is 0.60 percent up since the beginning of the trading day. The stock's lowest day price was 41.25. Basilea Pharmaceutica has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Basilea Pharmaceutica AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of January 2024 and ending today, the 19th of April 2024. Click here to learn more.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. The company has 11.93 M outstanding shares. More on Basilea Pharmaceutica AG
Moving against Basilea Stock
| 0.72 | RLF | Relief Therapeutics | PairCorr |
| 0.65 | MOLN | Molecular Partners | PairCorr |
| 0.61 | XLS | Xlife Sciences AG Earnings Call This Week | PairCorr |
| 0.54 | GALE | Galenica Sante AG | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Basilea Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Basilea Pharmaceutica's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Basilea Pharmaceutica or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Basilea Pharmaceutica AG (BSLN) is traded on SIX Swiss Exchange in Switzerland and employs 177 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 591.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Basilea Pharmaceutica's market, we take the total number of its shares issued and multiply it by Basilea Pharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Basilea Pharmaceutica operates under Healthcare sector and is part of Biotechnology industry. The entity has 11.93 M outstanding shares.
Basilea Pharmaceutica AG has accumulated about 0 in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.81.
Check Basilea Pharmaceutica Probability Of Bankruptcy
Ownership AllocationBasilea Pharmaceutica retains a total of 11.93 Million outstanding shares. Basilea Pharmaceutica AG shows 3.05 percent of its outstanding shares held by insiders and 28.93 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Basilea Ownership Details
Basilea Stock Price Odds Analysis
Depending on a normal probability distribution, the odds of Basilea Pharmaceutica jumping above the current price in 90 days from now is under 4%. The Basilea Pharmaceutica AG probability density function shows the probability of Basilea Pharmaceutica stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Basilea Pharmaceutica AG has a beta of -0.2923 suggesting as returns on the benchmark increase, returns on holding Basilea Pharmaceutica are expected to decrease at a much lower rate. During a bear market, however, Basilea Pharmaceutica AG is likely to outperform the market. Additionally, basilea Pharmaceutica AG has an alpha of 0.3959, implying that it can generate a 0.4 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Basilea Pharmaceutica to move above the current price in 90 days from now is under 4 (This Basilea Pharmaceutica AG probability density function shows the probability of Basilea Stock to fall within a particular range of prices over 90 days) .
Basilea Pharmaceutica Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Basilea Pharmaceutica market risk premium is the additional return an investor will receive from holding Basilea Pharmaceutica long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Basilea Pharmaceutica. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Basilea Pharmaceutica's alpha and beta are two of the key measurements used to evaluate Basilea Pharmaceutica's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.64 | |||
| Semi Deviation | 1.56 | |||
| Standard Deviation | 2.56 | |||
| Variance | 6.55 |
Basilea Stock Against Markets
Picking the right benchmark for Basilea Pharmaceutica stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Basilea Pharmaceutica stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Basilea Pharmaceutica is critical whether you are bullish or bearish towards Basilea Pharmaceutica AG at a given time. Please also check how Basilea Pharmaceutica's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Basilea Pharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Basilea Pharmaceutica Corporate Management
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lutz Wevelsiep | Head Affairs | Profile | |
| Adesh Kaul | Chief Officer | Profile | |
| Damian Heller | Gen Sec | Profile | |
| Gerrit Hauck | Chief Officer | Profile | |
| David Veitch | Chief Officer | Profile | |
| Ursula Eberhardt | Head HR | Profile | |
| Marc MD | Chief Officer | Profile |
How to buy Basilea Stock?
Before investing in Basilea Pharmaceutica, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Basilea Pharmaceutica. To buy Basilea Pharmaceutica stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Basilea Pharmaceutica. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Basilea Pharmaceutica stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Basilea Pharmaceutica AG stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Basilea Pharmaceutica AG stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Basilea Pharmaceutica AG, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Basilea Pharmaceutica AG?
The danger of trading Basilea Pharmaceutica AG is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Basilea Pharmaceutica is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Basilea Pharmaceutica. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Basilea Pharmaceutica is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Basilea Stock analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |